Search Results - "Kurokawa, Yosuke K."

A combined hiPSC-derived endothelial cell and in vitro microfluidic platform for assessing biomaterial-based angiogenesis by Natividad-Diaz, Sylvia L., Browne, Shane, Jha, Amit K., Ma, Zhen, Hossainy, Samir, Kurokawa, Yosuke K., George, Steven C., Healy, Kevin E.

“…Human induced pluripotent stem cell (hiPSC) derived angiogenesis models present a unique opportunity for patient-specific platforms to study the complex…”
Get full text

Enhanced drug classification using machine learning with multiplexed cardiac contractility assays by Aghavali, Reza, Roberts, Erin G., Kurokawa, Yosuke K., Mak, Erica, Chan, Martin Y.C., Wong, Andy O.T., Li, Ronald A., Costa, Kevin D.

“…Cardiac screening of newly discovered drugs remains a longstanding challenge for the pharmaceutical industry. While therapeutic efficacy and cardiotoxicity are…”
Get full text

Machine learning plus optical flow: a simple and sensitive method to detect cardioactive drugs by Lee, Eugene K., Kurokawa, Yosuke K., Tu, Robin, George, Steven C., Khine, Michelle

“…Current preclinical screening methods do not adequately detect cardiotoxicity. Using human induced pluripotent stem cell-derived cardiomyocytes (iPS-CMs), more…”
Get full text

Tissue engineering the cardiac microenvironment: Multicellular microphysiological systems for drug screening by Kurokawa, Yosuke K., George, Steven C.

“…The ability to accurately detect cardiotoxicity has become increasingly important in the development of new drugs. Since the advent of human pluripotent stem…”
Get full text

Modeling trastuzumab-related cardiotoxicity in vitro using human stem cell-derived cardiomyocytes by Kurokawa, Yosuke K., Shang, Michael R., Yin, Rose T., George, Steven C.

“…•Trastuzumab-related cardiotoxicity can be detected using iPS-CMs.•ErbB2/4 pathway activation is necessary to detect trastuzumab toxicity.•NRG-1 and HB-EGF…”
Get full text

Ultra‐Compliant Indwelling Elastomer Balloons Improve Stability and Performance of Bioengineered Human Mini‐Hearts by Roberts, Erin G., Mak, Suet Yee, Wong, Andy On-Tik, Tran, David D., Lee, Eugene K., Kurokawa, Yosuke K., Jennbacken, Karin, Wang, Qing‐Dong, Lieu, Deborah K., Hajjar, Roger J., Costa, Kevin D., Li, Ronald A.

“…Animal models used by the pharmaceutical industry to define drug safety and efficacy are expensive, resource‐intensive, subject to interspecies differences,…”
Get full text